Previous 10 | Next 10 |
2024-05-24 08:45:04 ET Palm Beach, FL – May 24, 2024 – The pancreatic cancer market encompasses the pharmaceutical and healthcare sectors dedicated to addressing the prevention, diagnosis, and treatment of pancreatic cancer, a particularly aggressive and often fatal form of ca...
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action PR Newswire Trial-in-progress abstract highlights new cohort that could expand the company's pancreatic cancer program Pelareorep's a...
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial Canada NewsWire Anticipated evaluation to include combination therapy featuring treatment regimen of checkpoint inhibition and chemotherapy...
2024-05-09 20:48:02 ET Oncolytics Biotech, Inc. (ONCY) Q1 2024 Earnings Conference Call May 09, 2024, 16:30 ET Company Participants Jon Patton - Director, Investor Relations and Communication Matthew Coffey - President, CEO & Director Thomas Heineman - Chief ...
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights Canada NewsWire Pelareorep advancing to registration-enabling studies Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2-...
2024-05-09 12:15:23 ET Palm Beach, FL – May 9, 2024 – FN Media Group News Commentary – The incidence of pancreatic cancer is increasing globally, which is driving the growth of the market. As of 2023, the American Cancer Society predicts that 64,050 American...
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer Canada NewsWire US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET st...
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference Canada NewsWire SAN DIEGO and CALGARY, AB , May 8, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading cl...
Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting Canada NewsWire SAN DIEGO and CALGARY, AB , April 25, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading c...
2024-04-11 10:00:56 ET More on Oncolytics Biotech Oncolytics Biotech, Inc. (ONCY) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Oncolytics Biotech Historical earnings data for Oncolytics Biotech Financial information for Oncolytics B...
News, Short Squeeze, Breakout and More Instantly...
Oncolytics Biotech Inc. Company Name:
ONCY Stock Symbol:
NASDAQ Market:
Oncolytics Biotech Inc. Website:
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program Canada NewsWire Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report ove...
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence Canada NewsWire Wayne Pisano , Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast ca...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...